Rep. Gilbert Ray Cisneros, Jr. Buys Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). In a filing disclosed on January 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in Supernus Pharmaceuticals stock on December 11th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Supernus Pharmaceuticals Stock Performance

Shares of SUPN stock traded down $1.54 on Thursday, hitting $50.26. The company’s stock had a trading volume of 653,443 shares, compared to its average volume of 639,934. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $29.16 and a fifty-two week high of $57.65. The company has a market capitalization of $2.88 billion, a PE ratio of -147.82, a PEG ratio of 0.50 and a beta of 0.67. The stock’s 50 day moving average is $47.82 and its 200-day moving average is $44.77.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). The business had revenue of $170.00 million for the quarter, compared to analyst estimates of $175.82 million. Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.69 EPS. On average, research analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently commented on SUPN shares. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Zacks Research lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Bank of America began coverage on Supernus Pharmaceuticals in a report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target for the company. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $40.00 to $65.00 in a research note on Thursday, October 9th. Finally, Wall Street Zen raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $61.60.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its holdings in Supernus Pharmaceuticals by 2.9% in the second quarter. State Street Corp now owns 2,208,560 shares of the specialty pharmaceutical company’s stock valued at $69,614,000 after acquiring an additional 63,210 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,399,610 shares of the specialty pharmaceutical company’s stock valued at $44,121,000 after purchasing an additional 72,991 shares during the last quarter. Woodline Partners LP increased its position in shares of Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares during the period. Bank of America Corp DE increased its position in shares of Supernus Pharmaceuticals by 67.1% during the third quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock worth $40,282,000 after buying an additional 338,584 shares during the period. Finally, Sofinnova Investments Inc. raised its stake in Supernus Pharmaceuticals by 53.5% during the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after buying an additional 278,575 shares during the last quarter.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 20,000 shares of the company’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at $781,153.36. This represents a 56.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the sale, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. This represents a 4.67% decrease in their position. The disclosure for this sale is available in the SEC filing. 8.80% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.